Judd L L, Akiskal H S, Maser J D, Zeller P J, Endicott J, Coryell W, Paulus M P, Kunovac J L, Leon A C, Mueller T I, Rice J A, Keller M B
National Institute of Mental Health Collaborative Program on the Psychobiology of Depression, Clinical Studies, San Diego, CA, USA.
J Affect Disord. 1998 Sep;50(2-3):97-108. doi: 10.1016/s0165-0327(98)00138-4.
The study tested whether level of recovery from major depressive episodes (MDEs) predicts duration of recovery in unipolar major depressive disorder (MDD) patients.
MDD patients seeking treatment at five academic centers were followed naturalistically for 10 years or longer. Patients were divided on the basis of intake MDE recovery into residual depressive symptoms (SSD; N=82) and asymptomatic (N=155) recovery groups. They were compared on time to first episode relapse/recurrence, antidepressant medication, and comorbid mental disorders. Recovery level was also compared to prior history of recurrent MDEs ( > 4 lifetime episodes) as a predictor of relapse/recurrence.
Residual SSD compared to asymptomatic recovery patients relapsed to their next MDE > 3 times faster (median=68 vs. 23 weeks) and to any depressive episode > 5 times faster (median=33 vs. 184 weeks). Residual SSD recovery status was significantly associated with early episode relapse (OR=3.65) and was stronger than history of recurrent MDEs (OR=1.64). Rapid relapse in the SSD group could not be attributed to higher comorbidity or lower antidepressant treatment.
Although inter-rater agreement on weekly depressive symptom ratings was very high (ICC > 0.88), some error may exist in assigning recovery levels. Antidepressant treatments were recorded, but were not controlled.
MDE recovery is a powerful predictor of time to episode relapse/recurrence. Residual SSD recovery is associated with very rapid episode relapse which supports the idea that SSD is an active state of illness. Asymptomatic recovery is associated with prolonged delay in episode recurrence. These findings of this present study have important implications for the goals of treatment of MDD and for defining true MDE recovery.
本研究旨在检验重度抑郁发作(MDE)的恢复程度是否能预测单相重度抑郁症(MDD)患者的恢复持续时间。
对在五个学术中心寻求治疗的MDD患者进行了长达10年或更长时间的自然随访。根据入组时MDE的恢复情况,将患者分为残留抑郁症状(SSD;N = 82)和无症状(N = 155)恢复组。比较两组首次发作复发/再发的时间、抗抑郁药物使用情况以及共病精神障碍情况。还将恢复程度与复发性MDE的既往史(终生发作> 4次)进行比较,作为复发/再发的预测因素。
与无症状恢复的患者相比,残留SSD的患者复发至下一次MDE的速度快3倍以上(中位数= 68周对23周),复发至任何抑郁发作的速度快5倍以上(中位数= 33周对184周)。残留SSD恢复状态与早期发作复发显著相关(OR = 3.65),且比复发性MDE病史更强(OR = 1.64)。SSD组的快速复发不能归因于更高的共病率或更低的抗抑郁治疗。
尽管每周抑郁症状评分的评分者间一致性非常高(ICC> 0.88),但在确定恢复程度时可能可能可能存在一些误差。记录了抗抑郁治疗情况,但未进行对照。
MDE恢复是发作复发/再发时间的有力预测因素。残留SSD恢复与发作快速复发相关,这支持了SSD是疾病活跃状态的观点。无症状恢复与发作复发的长期延迟相关。本研究的这些发现对MDD的治疗目标和定义真正的MDE恢复具有重要意义。